Hilleman Laboratories Pvt. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hilleman Laboratories Pvt. Ltd.
A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery
India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?
While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to Scrip on which one stands a better chance of winning.
As more countries adopt heterologous boosting of COVID-19 vaccines in a bid to improve supplies and/or immunity while reducing side effects, vaccines expert and ex-Hilleman CEO Davinder Gill talks to Scrip in an audio interview on the challenges of the strategy and of the disease becoming endemic.
- Academic and Research Institutions